Pro-Dex, Inc.

NASDAQ:PDEX

Medical - Instruments & Supplies

Healthcare
$63.94 +5.86%

+$3.54 today

Market cap
$204.61M
Beta
-0.00
P/E (TTM)
17.1
EPS (TTM)
$3.75
52W Low $23.47High $68.99

Volume 0.04M

Average 0.04M

PDEX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Pro-Dex, Inc.NASDAQ: PDEX

Gross Margin · Q3 FY2026 · quarter ended Mar 2026

Gross margin narrows to 30.7%

Gross margin was 30.7% in Q3 FY2026, down 2.6 pp from a year earlier. On a trailing-twelve-month basis it was 27.8%, down 3.6 pp year over year. Over 3 fiscal years it narrowed by 1.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
30.7%-0.0 pp QoQ
Last fiscal yearJun 2025
29.3%+2.3 pp YoY
LTMMar 2026
27.8%-3.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.6 pp——
1 year+2.3 pp——
3 years-1.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.3%
Year-over-year change
+2.3pp

Gross Margin vs competitors

How PDEX compares with its peers on the latest reported figures

  • PDEX's LTM Mar 2026 gross margin of 27.8% is the 2nd highest of the 7 companies compared; the peer median is -24.8%.
  • Its year-over-year change of -3.6 pp is the 3rd highest of 5, against a peer median of -6.5 pp.
  • Over three fiscal years its change of -1.9 pp compares with a peer median of +21.5 pp.
PDEX Competitors Peer median
Gross Margin for PDEX and competitors
Company Period LTM level YoY 3-year change
APYXApyx Medical CorporationLTM Mar 202632.3% -19.3 pp-29.4 pp
PDEXPro-Dex, Inc.LTM Mar 202627.8% -3.6 pp-1.9 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 202612.4% +6.3 pp+72.5 pp
MBOTMicrobot Medical Inc.LTM Mar 2026-9.5% ——
LUCDLucid Diagnostics Inc.LTM Mar 2026-40.0% +27.6 pp+798.4 pp
STSSSkyAI, Inc.LTM Mar 2026-106.6% ——
SERASera Prognostics, Inc.LTM Mar 2026-191.2% -199.9 pp-130.5 pp
GLSIGreenwich LifeSciences, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
Peer median (excluding PDEX) -24.8%-6.5 pp+21.5 pp

Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue42.04M42.04M46.09M53.84M66.59M
Cost of Revenue28.91M28.91M33.34M39.29M47.08M
Gross Profit13.13M13.13M12.75M14.55M19.51M
Gross Margin31.2%31.2%27.7%27.0%29.3%
Research & Development2.98M2.98M2.8M3.19M3.64M
Selling, General & Admin4.99M4.99M4.18M4.19M5.19M
Operating Expenses8.01M8.01M6.99M7.38M8.82M
Depreciation & Amortization726K726K857K1.16M1.24M
EBITDA6.88M6.88M10.82M4.35M14.13M
EBITDA Margin16.4%16.4%23.5%8.1%21.2%
Operating Income5.12M5.12M5.76M7.17M10.69M
Operating Margin12.2%12.2%12.5%13.3%16.1%
Interest Income126K76K294K144K82K
Interest Expense352K464K533K558K829K
Other Income / Expenses571K571K3.67M(4.54M)1.37M
Income Before Tax5.69M5.69M9.43M2.63M12.06M
Pre-Tax Margin13.5%13.5%20.5%4.9%18.1%
Income Tax Expense1.12M1.12M2.35M507K3.08M
Net Income4.57M4.57M7.07M2.13M8.98M
Net Margin10.9%10.9%15.3%4.0%13.5%
EPS (Basic)1.171.261.980.612.73
EPS (Diluted)1.131.211.950.602.67
Weighted Avg Shares3.8M3.64M3.57M3.5M3.29M
Weighted Avg Shares (Diluted)3.94M3.76M3.64M3.57M3.36M

Pro-Dex, Inc.

NASDAQ:PDEX

Intrinsic Alpha fair value

Locked

Current Price

$63.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.